SCHEMBL29414896

SCHEMBL29414896

Cc1cc([N+](=O)[O-])ccc1Oc1ccnc(N)c1

nearest known ligand 0.49

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.49
TDP1 Q9NUW8 3/20 0.49
CYP3A4 P08684 2/20 0.49
MEN1 O00255 6/20 0.46
KMT2A Q03164 6/20 0.46
MAPT P10636 4/20 0.46
PDE7A Q13946 1/20 0.45
TSHR P16473 2/20 0.44
NOS3 P29474 1/20 0.43
NOS1 P29475 1/20 0.43
NOS2 P35228 1/20 0.43
HTT P42858 4/20 0.42
GAA P10253 2/20 0.41
LMNA P02545 2/20 0.41
KDM4E B2RXH2 1/20 0.41
GLA P06280 1/20 0.41
THRB P10828 1/20 0.41
HSPB1 P04792 1/20 0.40
MAPK1 P28482 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1192691 1.00 ALDH1A1 (0.49) ALDH1A1TDP1CYP3A4MEN1KMT2A
SCHEMBL2475433 0.86 HTT (0.55) ALDH1A1TDP1MEN1KMT2AMAPT
SCHEMBL24168282 0.84 PDE7A (0.45) ALDH1A1TDP1CYP3A4MEN1KMT2A
SCHEMBL29414899 0.84 PDE7A (0.45) ALDH1A1TDP1CYP3A4MEN1KMT2A
SCHEMBL197935 0.84 HSPB1 (0.53) ALDH1A1TDP1MEN1KMT2AMAPT
SCHEMBL30844467 0.84 HSPB1 (0.53) ALDH1A1TDP1MEN1KMT2AMAPT
SCHEMBL4340804 0.84 PDE7A (0.65) ALDH1A1CYP3A4MEN1KMT2AMAPT
SCHEMBL30222233 0.84 PDE7A (0.65) ALDH1A1CYP3A4MEN1KMT2AMAPT
SCHEMBL15015164 0.84 ALDH1A1 (0.42) ALDH1A1TDP1CYP3A4MEN1KMT2A
SCHEMBL29414902 0.84 ALDH1A1 (0.42) ALDH1A1TDP1CYP3A4MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-122079960-A Alkynyl quinazoline compounds 2026-05-26 CN disclosed
CN-119390683-A Alkynyl quinazoline compounds 黑钻治疗公司 2025-02-07 CN disclosed
EP-4380941-A1 TRICYCLIC FUSED PYRIMIDINE COMPOUNDS FOR USE AS HER2 INHIBITORS Bristol-Myers Squibb Company (US) 2024-06-12 EP disclosed
CN-117980309-A Tricyclic fused pyrimidine compounds useful as HER2 inhibitors 百时美施贵宝公司 2024-05-03 CN disclosed
EP-4267137-A1 LACTAM (HETERO)ARYLFUSEDPYRIMIDINE DERIVATIVES AS INHIBITORS OF ERBB2 Enliven Inc. (US) 2023-11-01 EP disclosed
CN-114907339-B 4- (4-aminophenoxy) pyridin-2-amine derivatives and use thereof 成都奥睿药业有限公司 2023-07-14 CN disclosed
CN-109422755-B Nitrogen-containing heterocyclic compound, preparation method, intermediate, composition and application 上海医药集团股份有限公司 2023-07-04 CN disclosed
WO-2023015240-A1 TRICYCLIC FUSED PYRIMIDINE COMPOUNDS FOR USE AS HER2 INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2023-02-09 WO disclosed
CN-114907339-A 4- (4-aminophenoxy) pyridin-2-amine derivatives and uses thereof 成都奥睿药业有限公司 2022-08-16 CN disclosed
WO-2022140769-A1 LACTAM (HETERO)ARYLFUSEDPYRIMIDINE DERIVATIVES AS INHIBITORS OF ERBB2 ENLIVEN THERAPEUTICS, INC. (US) 2022-06-30 WO disclosed
CN-114031619-A Preparation method of intermediate of Tecatinib 山东汇海医药化工有限公司 2022-02-11 CN disclosed